Scinai Immunotherapeutics Files 6-K Report
Ticker: SCNI · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, company-update
Related Tickers: SCIN
TL;DR
Scinai (SCIN) filed a 6-K for Q2 2025, former BiondVax.
AI Summary
Scinai Immunotherapeutics Ltd. filed a Form 6-K on September 2, 2025, reporting information for the period ending June 30, 2025. The filing includes a press release from the company. Scinai Immunotherapeutics was formerly known as BiondVax Pharmaceuticals Ltd. until a name change on June 24, 2014.
Why It Matters
This filing provides an update on Scinai Immunotherapeutics' activities and financial reporting for the period ending June 30, 2025, which is important for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as a report of foreign private issuer information and does not contain significant new financial or strategic disclosures.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer
- BiondVax Pharmaceuticals Ltd. (company) — Former company name
- June 30, 2025 (date) — Period of report
- September 2, 2025 (date) — Filing date
- June 24, 2014 (date) — Date of name change
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report information as a foreign private issuer, including attached press releases, for the period ending June 30, 2025.
What was Scinai Immunotherapeutics Ltd. previously known as?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
When did the company change its name?
The company's name change from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. occurred on June 24, 2014.
What is the principal executive office address for Scinai Immunotherapeutics Ltd.?
The principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Does Scinai Immunotherapeutics Ltd. file annual reports on Form 20-F or 40-F?
Yes, Scinai Immunotherapeutics Ltd. files its annual reports under cover of Form 20-F.
Filing Stats: 349 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2025-09-02 16:16:10
Filing Documents
- ea0255452-6k_scinai.htm (6-K) — 18KB
- ea025545201ex99-1_scinai.htm (EX-99.1) — 16KB
- ea025545201ex99-2_scinai.htm (EX-99.2) — 286KB
- ea025545201ex99-3_scinai.htm (EX-99.3) — 52KB
- ex99-1_001.jpg (GRAPHIC) — 26KB
- 0001213900-25-083373.txt ( ) — 2545KB
- scni-20250630.xsd (EX-101.SCH) — 28KB
- scni-20250630_cal.xml (EX-101.CAL) — 24KB
- scni-20250630_def.xml (EX-101.DEF) — 131KB
- scni-20250630_lab.xml (EX-101.LAB) — 264KB
- scni-20250630_pre.xml (EX-101.PRE) — 145KB
- ea0255452-6k_scinai_htm.xml (XML) — 183KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: September 2, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2